ACTA SCIENTIAE

ISSN: 2178-7727

Pharmacological Evaluation of Hepatoprotective Polyherbal Formulations Prepared from Tinospora cordifolia, Boerhavia diffusa, Moringa oleifera and Phyllanthus emblica

Mr. Bhushan Pravin Patil[1], Prof. Dr. Mohammed Rageeb Mohammed Usman*, Dr. Abdul Hafeez[2]

[1]Ph.D. Scholar, Glocal School of Pharmacy, Glocal University, UP, India *Smt. Sharadchandrika Suresh Patil College of Pharmacy, Chopda, Maharashtra, India
[2]Glocal School of Pharmacy, Glocal University, UP, India

ABSTRACT

Liver disorders remain a major global health burden, and conventional hepatoprotective drugs are limited by cost, availability, and side effects, driving renewed interest in polyherbal formulations. This study evaluates the pharmacological rationale and evidence base for a polyherbal formulation combining Tinospora cordifolia, Boerhavia diffusa, Moringa oleifera, and Phyllanthus emblica — four plants independently reported to possess hepatoprotective, antioxidant, and anti-inflammatory properties. The research problem addressed is the absence of a consolidated pharmacological evaluation framework for this specific four-plant combination, despite strong individual evidence for each constituent. A structured evaluation protocol was designed using the carbon-tetrachloride (CCl_4)-induced hepatotoxicity model in Wistar rats, with biochemical liver markers (SGPT, SGOT, ALP, total bilirubin), antioxidant enzyme assays, and histopathological scoring as primary endpoints, alongside standard statistical evaluation (one-way ANOVA with Dunnett's post-hoc test). The evaluation draws on convergent literature evidence indicating that individual and related polyherbal combinations of these plant families typically produce 40–70% restoration of elevated liver enzymes toward normal values, with dose-dependent antioxidant enhancement. The formulation's proposed mechanism operates through free-radical scavenging, membrane stabilization, and hepatocyte regeneration support. The study concludes that the four-plant combination has strong literature-supported pharmacological rationale and proposes a validated, reproducible protocol for future experimental confirmation. This work contributes a consolidated evidence synthesis, a standardized evaluation design, and quantitative benchmarking equations that can guide subsequent in vivo trials of this and related polyherbal hepatoprotective formulations.

KEYWORDS: Hepatoprotective Activity; Polyherbal Formulation; Tinospora Cordifolia; Boerhavia Diffusa; Ccl_4-Induced Hepatotoxicity; Liver Biomarkers; Herbal Pharmacology

INTRODUCTION

Liver diseases, including hepatitis, cirrhosis, and drug- or toxin-induced hepatotoxicity, account for a substantial share of global morbidity, with the liver's central metabolic role making it especially vulnerable to xenobiotic and oxidative damage [1]. Conventional hepatoprotective pharmacotherapy is limited: few synthetic agents are approved specifically for hepatoprotection, and existing options such as silymarin, while effective, are not universally accessible in resource-constrained settings [2]. This has sustained global and Indian interest in traditional and herbal hepatoprotective agents, many of which are documented in Ayurveda and validated to varying degrees by modern pharmacological research [3].

Among Indian medicinal plants, *Tinospora cordifolia* (Guduchi) and *Boerhavia diffusa* (Punarnava) are among the most extensively studied for hepatoprotective and immunomodulatory activity, with multiple rodent studies confirming their capacity to normalize liver enzyme levels after chemical or alcohol-induced damage [4]. *Phyllanthus emblica* (Amla) is independently well documented for potent antioxidant activity attributable to its high polyphenol and vitamin C content, which supports hepatocellular protection against oxidative stress [5]. *Moringa oleifera*, while more commonly studied for nutritional and antidiabetic properties, has also demonstrated hepatoprotective effects in several toxin-induced liver injury models,

DOI: 10.22178/acta.25.2.27

ISSN: 2178-7727

primarily through antioxidant and anti-inflammatory pathways [6].

Despite this substantial body of single-plant and partially overlapping polyherbal evidence, no consolidated pharmacological evaluation has specifically examined the combination of these four plants together, even though their individually reported mechanisms — antioxidant, membrane-stabilizing, anti-inflammatory, and regenerative — are pharmacologically complementary rather than redundant [7]. This represents both a scientific and a formulation-design gap: polyherbal combinations are traditionally assembled on empirical or Ayurvedic reasoning, but a pharmacologically reasoned, literature-triangulated rationale specific to this four-plant combination has not been assembled and evaluated using a standardized modern toxicology protocol.

The purpose of this study is therefore to construct and pharmacologically justify a defined polyherbal formulation from these four plants, to design a rigorous and reproducible evaluation protocol based on the internationally accepted CCl_4-hepatotoxicity model, and to synthesize the quantitative evidence base that predicts and benchmarks the formulation's expected hepatoprotective performance. The specific objectives are: (i) to define a standardized formulation composition; (ii) to design a complete pharmacological evaluation protocol including biochemical and histopathological endpoints; (iii) to synthesize literature-reported hepatoprotective outcomes for the same or closely related plant combinations as a quantitative benchmark; and (iv) to propose statistical evaluation criteria for confirming hepatoprotective efficacy in a subsequent experimental trial. The remainder of this paper proceeds as follows: Section 2 reviews relevant literature and situates the research gap; Section 3 presents the methodology; Section 4 describes the experimental setup; Section 5 presents the synthesized results and benchmarking framework; Section 6 discusses the pharmacological and practical implications; and Section 7 concludes.

LITERATURE REVIEW

Hepatoprotection research is grounded in the toxicological model of chemically induced liver injury, in which agents such as carbon tetrachloride, paracetamol, or ethanol generate reactive free radicals that damage hepatocyte membranes, elevate serum liver enzymes, and trigger inflammatory and fibrotic cascades [8]. The CCl_4 model remains the most widely used experimental standard because its mechanism — cytochrome P450-mediated formation of the trichloromethyl radical — closely mimics oxidative hepatocellular injury and produces reproducible, dose-dependent elevations in SGPT, SGOT, alkaline phosphatase, and bilirubin, making it suitable for comparative efficacy testing [9].

Tinospora cordifolia has been the subject of numerous hepatoprotection studies; ethanolic and aqueous extracts have consistently reduced CCl_4-, paracetamol-, and alcohol-induced elevations in liver enzymes in rodent models, with proposed mechanisms including free-radical scavenging and hepatocyte membrane stabilization [10]. *Boerhavia diffusa* extracts have shown comparable antioxidant and hepatoprotective activity, and combined *T. cordifolia–B. diffusa* extracts have demonstrated significant hepatoprotective and antioxidant effects in Swiss albino mice, supporting the pharmacological compatibility of these two plants when combined [11].

Polyherbal hepatoprotective research has expanded considerably in the past decade. Dey et al. formulated BV-7310, a standardized combination of *Phyllanthus niruri*, *Tephrosia purpurea*, *Boerhavia diffusa*, and *Andrographis paniculata*, and demonstrated that the formulation significantly protected HepG2 cells against alcohol-induced toxicity (approximately 42% toxicity in untreated controls) in a dose-dependent manner, alongside protective effects in an alcohol-plus-CCl_4 rat model, illustrating that structurally similar four-plant polyherbal combinations sharing *Boerhavia diffusa* as a common constituent can achieve statistically significant hepatoprotection across both in vitro and in vivo systems [12]. A systematic review by Aladejana further synthesized multiple polyherbal hepatoprotective studies, reporting that formulations combining *Tinospora cordifolia*, *Boerhavia diffusa*, *Phyllanthus* species, and other complementary plants consistently and significantly reduced serum liver enzyme levels in paracetamol- and D-galactosamine-induced rodent models across a range of tested doses [13].

DOI: 10.22178/acta.25.2.27

ISSN: 2178-7727

Independently, *Phyllanthus emblica* has been repeatedly shown to reduce oxidative liver damage owing to its exceptionally high ascorbic acid and tannin content, which enhances endogenous antioxidant enzyme activity (superoxide dismutase, catalase, glutathione peroxidase) in hepatic tissue [14]. *Moringa oleifera* leaf extract has similarly demonstrated significant reduction of CCl_4- and antitubercular-drug-induced liver enzyme elevation in rat models, attributed to its flavonoid and phenolic acid content [15].

Collectively, this literature establishes strong, largely independent pharmacological evidence for each of the four plants and for closely related polyherbal combinations sharing one or more of the same constituents. However, existing polyherbal hepatoprotection studies have predominantly examined combinations of three plants at most, and none identified in the current review specifically combines *Tinospora cordifolia*, *Boerhavia diffusa*, *Moringa oleifera*, and *Phyllanthus emblica* together. Furthermore, comparative benchmarking across studies is hindered by inconsistent dosing, extraction methods, and reporting of statistical outcomes. This represents a methodological gap (lack of a standardized four-plant evaluation protocol), an empirical gap (no direct trial of this specific combination), and a synthesis gap (no consolidated quantitative benchmark drawn from the converging individual-plant evidence). The present study addresses these gaps by formalizing the formulation and evaluation protocol and by constructing a literature-triangulated performance benchmark against which a future experimental trial can be evaluated.

METHODOLOGY

This study adopts a translational pharmacological research design comprising three components: (i) formulation design, (ii) protocol design for in vivo hepatoprotective evaluation, and (iii) evidence-synthesis benchmarking. The research approach is quantitative and hypothesis-driven, structured around the internationally accepted CCl_4-induced hepatotoxicity paradigm [16].

Formulation design. Shade-dried plant parts (*T. cordifolia* stem, *B. diffusa* whole plant, *M. oleifera* leaves, *P. emblica* fruit) are to be individually extracted using a Soxhlet apparatus with hydroalcoholic solvent (ethanol:water, 70:30), concentrated under reduced pressure, and combined in a defined ratio (Table 1) selected to balance each plant's relative potency as reported in the literature reviewed in Section 2.

Evaluation protocol. The proposed in vivo design follows a randomized parallel-group structure with six groups of six Wistar rats each (Table 2): normal control, toxic control (CCl_4 only), standard control (silymarin 100 mg/kg + CCl_4), and three polyherbal-formulation dose groups (200, 400, and 600 mg/kg + CCl_4), administered orally for seven days with CCl_4 challenge (1 mL/kg, 1:1 in olive oil, i.p.) on day 7 [17]. Primary endpoints are serum SGPT, SGOT, ALP, and total bilirubin, assayed spectrophotometrically 24 hours post-CCl_4 challenge; secondary endpoints are hepatic antioxidant markers (superoxide dismutase, catalase, malondialdehyde) and histopathological scoring of liver sections (necrosis, fatty change, inflammatory infiltration) on a semi-quantitative 0–4 scale [18].

Statistical evaluation plan. Data are to be expressed as mean ± SEM and analyzed by one-way ANOVA followed by Dunnett's post-hoc test comparing each treatment group to the toxic control, with $p < 0.05$ considered significant. Percentage hepatoprotection is computed using Equation (1):

%,Hepatoprotection = \frac{(T_c - T_t)}{(T_c - N_c)} \times 100

where T_c is the mean biomarker value of the toxic control group, T_t is the mean biomarker value of the treatment group, and N_c is the mean biomarker value of the normal control group. This equation expresses, as a percentage, how far a treatment group's biomarker level has moved from the toxic (fully damaged) state back toward the normal (undamaged) baseline; a value of 100% indicates complete normalization.
Extraction efficiency is quantified using Equation (2):

$$\%, Yield = \frac{W_e}{W_d} \times 100$$

where W_e is the weight of the dried extract obtained and W_d is the weight of the dry crude plant material used, providing a standard measure of extraction process efficiency.

DOI: 10.22178/acta.25.2.27

ISSN: 2178-7727

Antioxidant activity of the formulation (in vitro DPPH radical scavenging assay, conducted as a supporting evaluation) is quantified using Equation (3):

$$\%, Scavenging = \frac{(A_c - A_s)}{A_c} \times 100$$

where A_c is the absorbance of the DPPH control (no test sample) and A_s is the absorbance of the reaction mixture containing the test sample, both measured at 517 nm.

Group comparisons are evaluated using the one-way ANOVA F-statistic, Equation (4):

$$F = \frac{MS_{between}}{MS_{within}} = \frac{\sum_{i=1}^{k} n_i(\bar{x}i - \bar{x})^2/(k-1)}{\sum i = 1^{k} \sum_{j=1}^{n_i}(x_{ij} - \bar{x}_i)^2/(N-k)}$$

where k is the number of groups, n_i is the sample size of group i, $\bar{x}i$ *is the group mean,* $\bar{}\{x\}$ *is the grand mean,* xij is an individual observation, and N is the total sample size; a large F-value relative to the critical value indicates that between-group differences (treatment effects) exceed what would be expected from within-group variability alone.

Ethical considerations require prior institutional animal ethics committee (IAEC/CPCSEA-equivalent) approval, adherence to ARRIVE guidelines for animal research reporting, and use of the minimum animal number statistically justified by power analysis [19]. Methodological limitations of this design include species-to-human extrapolation uncertainty, the acute nature of the CCl_4 model relative to chronic human liver disease, and potential extract standardization variability across batches, all of which are addressed through triplicate extraction batches and HPTLC fingerprinting for batch consistency [20].



Figure 1 — Research Methodology Framework.

ISSN: 2178-7727

EXPERIMENTAL SETUP

The proposed experimental environment consists of a certified small-animal pharmacology laboratory equipped with a Soxhlet extraction unit, rotary vacuum evaporator, UV-visible spectrophotometer for biochemical assays, semi-automated biochemistry analyzer for SGPT/SGOT/ALP/bilirubin quantification, and a histopathology unit with microtome and light microscope for liver-section scoring. Wistar rats (150–200 g, either sex) would be acclimatized for seven days under standard conditions (22 ± 2 °C, 12-hour light/dark cycle, ad libitum feed and water) prior to grouping.

Extract standardization parameters to be recorded include loss on drying, total ash value, water- and alcohol-soluble extractive values, and phytochemical screening (alkaloids, glycosides, flavonoids, tannins, saponins) using standard pharmacopoeial reagent tests, with high-performance thin-layer chromatography (HPTLC) fingerprinting used to confirm the presence of characteristic marker compounds (e.g., berberine for *T. cordifolia*, gallic acid for *P. emblica*) across extraction batches. Dosing solutions are prepared fresh daily by suspending the dried formulation in 0.5% carboxymethyl cellulose and administered by oral gavage at a fixed volume of 1 mL/100 g body weight.

The baseline/comparison arm uses silymarin (100 mg/kg), the most widely validated reference hepatoprotective standard in the literature reviewed in Section 2, allowing the test formulation's performance to be benchmarked against an established positive control rather than against the toxic control alone. Each treatment arm requires a minimum of six animals based on standard power calculations ($\alpha = 0.05$, power = 0.80, expected effect size drawn from comparable published polyherbal studies), and the full protocol is designed to be executed once as a definitive confirmatory trial rather than multiple exploratory runs, consistent with 3Rs (Replacement, Reduction, Refinement) principles in animal research.



Figure 2 — Experimental/Implementation Setup.

ACTA SCIENTIAE

ISSN: 2178-7727

RESULTS

Because this paper presents a designed and literature-benchmarked evaluation protocol rather than a completed animal trial, this section synthesizes quantitative outcome patterns reported for this plant combination and its closest published analogues, to serve as the expected-performance benchmark against which a future confirmatory trial would be evaluated, rather than reporting original in vivo data.

Across the polyherbal hepatoprotection literature reviewed in Section 2, formulations combining *Tinospora cordifolia*, *Boerhavia diffusa*, and related *Phyllanthus* species have consistently produced statistically significant ($p < 0.05$) reductions in CCl_4- or paracetamol-elevated SGPT, SGOT, ALP, and bilirubin, with reported hepatoprotection in the range of approximately 45–75% at mid-to-high doses (200–400 mg/kg), calculated using the percentage-hepatoprotection formula in Equation (1) [12,13]. In the BV-7310 formulation sharing *Boerhavia diffusa* as a common constituent, alcohol-induced HepG2 cytotoxicity of approximately 42% was significantly and dose-dependently reduced by co-incubation with the formulation, with synergistic protection exceeding that of any single constituent extract tested alone [12]. Independently, *Phyllanthus emblica* and *Moringa oleifera* extracts have each been reported to restore antioxidant enzyme activity (SOD, catalase) toward normal levels at comparable dose ranges, reinforcing the expectation that their inclusion would contribute an additive antioxidant effect to the four-plant formulation [14,15].

Table 3 consolidates these literature-reported outcome ranges by constituent plant and endpoint, providing the quantitative benchmark against which the confirmatory trial designed in Section 3 is expected to be evaluated: a formulation performing within or above these established ranges, with statistically significant Dunnett's-test separation from the toxic control at the mid dose (400 mg/kg) or lower, would be considered to have met the a priori efficacy criterion for this study.

Table 1. Proposed Composition of the Polyherbal Formulation

Plant (part used)	Common/Ayurvedic name	Extract type	Proportion in formulation
Tinospora cordifolia (stem)	Guduchi	Hydroalcoholic (70:30)	30%
Boerhavia diffusa (whole plant)	Punarnava	Hydroalcoholic (70:30)	25%
Moringa oleifera (leaves)	Sahjan	Hydroalcoholic (70:30)	25%
Phyllanthus emblica (fruit)	Amla	Hydroalcoholic (70:30)	20%

Table 2. Proposed Animal Grouping and Dosing Protocol

Group	Treatment	Dose	n
I – Normal control	Vehicle only	—	6
II – Toxic control	CCl_4 (1 mL/kg, i.p.)	—	6
III – Standard	Silymarin + CCl_4	100 mg/kg	6
IV – Low dose	Formulation + CCl_4	200 mg/kg	6
V – Mid dose	Formulation + CCl_4	400 mg/kg	6
VI – High dose	Formulation + CCl_4	600 mg/kg	6

Table 3. Literature-Benchmarked Hepatoprotective Outcome Ranges for Related Formulations

Endpoint	Reported outcome range	Representative source(s)
SGPT/SGOT reduction (% hepatoprotection)	45–75% at 200–400 mg/kg	[12], [13]
HepG2 cell viability restoration	Significant, dose-dependent, vs. ~42% baseline toxicity	[12]

DOI: 10.22178/acta.25.2.27

Antioxidant enzyme (SOD/catalase) restoration	Significant increase toward normal at comparable doses	[14], [15]
Histopathological improvement	Reduced necrosis/fatty change scores at mid-high dose	[13]



Figure 3 — Benchmark Comparison Chart

DISCUSSION

The synthesized evidence indicates strong pharmacological plausibility for the proposed four-plant formulation. Each constituent independently targets a complementary mechanism — *T. cordifolia* and *B. diffusa* primarily through membrane stabilization and immunomodulation, *P. emblica* through direct antioxidant enzyme enhancement, and *M. oleifera* through anti-inflammatory and flavonoid-mediated radical scavenging — suggesting the combination is mechanistically additive rather than redundant, consistent with the synergistic effect reported for the structurally similar BV-7310 formulation [12]. This supports the study's underlying hypothesis that a rationally combined four-plant formulation should achieve hepatoprotection at least comparable to, and potentially exceeding, the individual-plant and three-plant combinations reported in existing literature.

These findings agree with the broader polyherbal hepatoprotection literature's conclusion that multi-plant combinations tend to outperform single-plant extracts, attributed to complementary phytochemical action and mutual potentiation of antioxidant pathways [13]. However, the discussion must also note an important limitation: benchmarking against literature-reported ranges for related but non-identical formulations cannot substitute for a direct confirmatory trial, since extraction method, dose ratio, and plant-part selection materially affect potency, and even closely related formulations have shown considerable inter-study variability in reported hepatoprotection percentages. The practical implication is that the protocol and equations developed in Section 3 provide a ready-to-execute, statistically powered design that removes methodological ambiguity from a future trial, while the literature synthesis in Section 5 provides a pre-registered, falsifiable performance benchmark rather than an assumed positive outcome.

Theoretically, this work contributes a consolidated mechanistic rationale for combining these specific four plants, an area not previously addressed as a unified formulation in the reviewed literature. Practically, it offers herbal formulation researchers and small-scale nutraceutical developers a standardized, reproducible protocol and benchmark, reducing the exploratory burden typically associated with novel polyherbal formulation

development. Future research should prioritize executing the designed CCl_4 trial, followed by chronic-toxicity and sub-acute safety studies, and eventual dose-optimization studies to identify the minimum effective dose.

CONCLUSION

This study developed a pharmacologically justified formulation combining *Tinospora cordifolia*, *Boerhavia diffusa*, *Moringa oleifera*, and *Phyllanthus emblica*, together with a complete, statistically powered evaluation protocol based on the CCl_4-induced hepatotoxicity model. By synthesizing convergent evidence from closely related polyherbal studies, the research establishes a quantitative benchmark (45–75% expected hepatoprotection at 200–400 mg/kg) against which the formulation's efficacy can be confirmatory-tested. The primary contribution is a reproducible, ethically sound experimental design paired with defined mathematical evaluation criteria (percentage hepatoprotection, extraction yield, antioxidant scavenging, and ANOVA-based statistical testing), addressing a clear gap in the literature regarding this specific four-plant combination. The work has both scientific significance, by proposing a mechanistically justified novel combination, and practical significance, for herbal-formulation developers seeking an evidence-based starting point. Future work should execute the proposed in vivo protocol to empirically confirm the benchmarked expectations established here.

REFERENCES

1. Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. *Journal of Hepatology*, 70(1), 151–171. https://doi.org/10.1016/j.jhep.2018.09.014
2. Gillessen, A., & Schmidt, H. H. J. (2020). Silymarin as supportive treatment in liver diseases: A narrative review. *Advances in Therapy*, 37(4), 1279–1301. https://doi.org/10.1007/s12325-020-01251-y
3. Girish, C., & Pradhan, S. C. (2012). Hepatoprotective activities of picroliv, curcumin, and ellagic acid compared to silymarin on carbon-tetrachloride-induced liver toxicity in mice. *Journal of Pharmacology and Pharmacotherapeutics*, 3(2), 149–155. https://doi.org/10.4103/0976-500X.95515
4. Sharma, P., Dwivedee, B. P., Bisht, D., Dash, A. K., & Kumar, D. (2019). The chemical constituents and diverse pharmacological importance of *Tinospora cordifolia*. *Heliyon*, 5(9), e02437. https://doi.org/10.1016/j.heliyon.2019.e02437
5. Variya, B. C., Bakrania, A. K., & Patel, S. S. (2016). Emblica officinalis (Amla): A review for its phytochemistry, ethnomedicinal uses and medicinal potentials with respect to molecular mechanisms. *Pharmacological Research*, 111, 180–200. https://doi.org/10.1016/j.phrs.2016.06.013
6. Vergara-Jimenez, M., Almatrafi, M. M., & Fernandez, M. L. (2017). Bioactive components in Moringa oleifera leaves protect against chronic disease. *Antioxidants*, 6(4), 91. https://doi.org/10.3390/antiox6040091
7. Aladejana, A. E. (2023). Hepatoprotective activities of polyherbal formulations: A systematic review. *Journal of Medicinal Plants for Economic Development*, 7(1), a206. https://doi.org/10.4102/jomped.v7i1.206
8. Weber, L. W., Boll, M., & Stampfl, A. (2003). Hepatotoxicity and mechanism of action of haloalkanes: Carbon tetrachloride as a toxicological model. *Critical Reviews in Toxicology*, 33(2), 105–136. https://doi.org/10.1080/713611034
9. Recknagel, R. O., Glende, E. A., Dolak, J. A., & Waller, R. L. (1989). Mechanisms of carbon tetrachloride toxicity. *Pharmacology & Therapeutics*, 43(1), 139–154. https://doi.org/10.1016/0163-7258(89)90050-8
10. Sharma, U., Bala, M., Kumar, N., Singh, B., Munshi, R. K., & Bhalerao, S. (2012). Immunomodulatory active compounds from *Tinospora cordifolia*. *Journal of Ethnopharmacology*, 141(3), 918–926. https://doi.org/10.1016/j.jep.2012.03.027
11. Antioxidant and hepatoprotective potential of Swaras and Hima extracts of *Tinospora cordifolia* and *Boerhavia diffusa* in Swiss albino mice. (2017). *Pharmacognosy Magazine*, 13(Suppl 3), S658–S662.
12. Dey, D., Chaskar, S., Bhatt, N., & Chitre, D. (2020). Hepatoprotective activity of BV-7310, a proprietary herbal formulation of *Phyllanthus niruri*, *Tephrosia purpurea*, *Boerhavia diffusa*, and *Andrographis paniculata*, in alcohol-induced HepG2 cells and alcohol plus a haloalkane, CCl_4,

ISSN: 2178-7727

induced liver damage in rats. *Evidence-Based Complementary and Alternative Medicine*, 2020, 6428906. https://doi.org/10.1155/2020/6428906

13. Aladejana, A. E. (2023). Hepatoprotective activities of polyherbal formulations: A systematic review. *Journal of Medicinal Plants for Economic Development*, 7(1), a206. https://doi.org/10.4102/jomped.v7i1.206
14. Sai Ram, M., Neetu, D., Yogesh, B., Anju, B., Dipti, P., Pauline, T., ... & Ilavazhagan, G. (2002). Cyto-protective and immunomodulating properties of Amla (*Emblica officinalis*) on lymphocytes. *Journal of Ethnopharmacology*, 81(1), 5–10. https://doi.org/10.1016/S0378-8741(01)00421-4
15. Fakurazi, S., Hairuszah, I., & Nanthini, U. (2008). *Moringa oleifera* Lam prevents acetaminophen-induced liver injury through restoration of glutathione level. *Food and Chemical Toxicology*, 46(8), 2611–2615. https://doi.org/10.1016/j.fct.2008.04.018
16. World Health Organization. (2000). *General guidelines for methodologies on research and evaluation of traditional medicine*. WHO/EDM/TRM/2000.1.
17. OECD. (2008). *Test No. 407: Repeated dose 28-day oral toxicity study in rodents*. OECD Guidelines for the Testing of Chemicals. https://doi.org/10.1787/9789264070684-en
18. Kleiner, D. E., Brunt, E. M., Van Natta, M., et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*, 41(6), 1313–1321. https://doi.org/10.1002/hep.20701
19. Percie du Sert, N., Hurst, V., Ahluwalia, A., et al. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. *PLOS Biology*, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
20. World Health Organization. (2011). *Quality control methods for herbal materials*. WHO Press.